Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 10/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173749 | 1.00 | HDAC4 (0.73) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL18311480 | 1.00 | HDAC4 (0.73) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL29355458 | 1.00 | HDAC4 (0.73) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL6248993 | 1.00 | HDAC4 (0.73) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL22286556 | 1.00 | HDAC4 (0.73) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL25986065 | 0.96 | HDAC4 (0.72) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL30540151 | 0.96 | HDAC4 (0.72) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL24614335 | 0.92 | HDAC4 (0.64) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL24614260 | 0.92 | HDAC4 (0.64) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL24614249 | 0.92 | HDAC4 (0.64) | HDAC4HDAC1HDAC6HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | MICROBA IP PTY LTD (AU) | 2026-01-29 | — | — | US | claimed |
| EP-4594325-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | Novmetapharma Co., Ltd. (KR) | 2025-08-06 | — | — | EP | claimed |
| CN-119775430-A | Mineral composite peptide and preparation and application thereof | 中国科学院烟台海岸带研究所 | 2025-04-08 | — | — | CN | claimed |
| US-12186312-B2 | Sleep improving agent | Amino Up Co., Ltd. (JP) | 2025-01-07 | — | — | US | claimed |
| CN-119072244-A | Bacterial strains for the treatment of diseases | 美克罗巴知识产权私人有限公司 | 2024-12-03 | — | — | CN | claimed |
| EP-4429482-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | Microba IP Pty Limited (AU) | 2024-09-18 | — | — | EP | claimed |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | claimed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | claimed |
| US-20230398158-A1 | NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS | LACTOBIO A/S (DK) | 2023-12-14 | — | — | US | claimed |
| EP-4240826-A1 | NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS | Lactobio A/S (DK) | 2023-09-13 | — | — | EP | claimed |
| WO-2023081980-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | MICROBA IP PTY LTD (AU) | 2023-05-19 | — | — | WO | claimed |
| US-20230017155-A1 | SLEEP IMPROVING AGENT | Amino Up Co., Ltd. (JP) | 2023-01-19 | — | — | US | claimed |
| WO-2022096573-A9 | NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS | LACTOBIO A/S (DK) | 2022-10-27 | — | — | WO | claimed |
| US-11478473-B2 | Sleep improving agent | Amino Up Co., Ltd. (JP) | 2022-10-25 | — | — | US | claimed |
| WO-2022096573-A1 | NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS | LACTOBIO A/S (DK) | 2022-05-12 | — | — | WO | claimed |
| CN-111378595-B | Burkholderia agricultural biocontrol strain Ba1 and application thereof | 中国林业科学研究院亚热带林业研究所 | 2021-04-27 | — | — | CN | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | MICROBA IP PTY LTD (AU) | 2026-01-29 | — | — | US | disclosed |
| US-20040024180-A1 | Process for the production of 2,5 -diketopiperazines,2,5-diketopiperazines , dipeptides and their use thereof | DEGUSSA AG (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1386543-A1 | New bacterial strain and the use thereof | Medipharm AB (SE) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | LNPEP, ANPEP, DNPEP | HDAC4 1691/4885HDAC1 506/4885HDAC6 1697/4885 |
| US-11478473-B2 | Sleep improving agent | HSF1, HSPH1, HSPA2 | HDAC4 126/4885HDAC1 254/4885HDAC6 208/4885 |
| US-20230017155-A1 | SLEEP IMPROVING AGENT | HSF1, HSPH1, HSPA2 | HDAC4 127/4885HDAC1 227/4885HDAC6 279/4885 |
| US-12186312-B2 | Sleep improving agent | HSF1, HSPH1, HSPA2 | HDAC4 127/4885HDAC1 227/4885HDAC6 279/4885 |
| US-20040024180-A1 | Process for the production of 2,5 -diketopiperazines,2,5-diketopiperazines , dipeptides and their use thereof | DHPS, DPP7, VIP | HDAC4 3488/4885HDAC1 3638/4885HDAC6 2121/4885 |
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | VIP, SI, ALPI | HDAC4 3455/4885HDAC1 3093/4885HDAC6 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.